Pykus Therapeutics is developing PYK-2101, a biodegradable retinal sealant that eliminates the need for facedown positioning and reduces blurred vision during recovery from retinal surgery. This technology addresses the significant post-operative burdens faced by patients, enhancing their overall recovery experience.
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Following retinal surgery, patients often face a challenging recovery period that includes strict facedown positioning, blurred vision, and restrictions on air travel, significantly impacting their quality of life. Current methods of retinal tamponade, such as gas or oil insertion, necessitate these burdensome post-operative requirements.
Solution
Pykus Therapeutics is developing PYK-2101, a novel biodegradable retinal sealant designed to eliminate the need for facedown positioning and reduce blurred vision during recovery from retinal surgery. This in situ crosslinking hydrogel is administered during the surgical procedure and supports retinal healing without the limitations associated with traditional gas or oil tamponades. By using PYK-2101, patients may avoid the discomfort and lifestyle disruptions typically experienced after vitrectomies, potentially improving overall recovery outcomes and reducing the need for repeat surgeries.
Target Audience
The primary target audience includes retinal surgeons and their patients undergoing vitrectomies for the treatment of serious eye diseases.
Features
- Biodegradable hydrogel composition designed for retinal tamponade
- In situ crosslinking for ease of application during surgery
- Designed to eliminate the need for facedown positioning post-surgery
- Aims to reduce blurred vision during the recovery period
- Intended to remove restrictions on air travel post-surgery
- Designed to reduce the need for repeat surgeries